Revenue Momentum Aquestive Therapeutics shows recent quarterly revenue beats with July 2026 revenue around 13.8 million, signaling a positive buying environment for outsourced formulations, delivery technologies, or manufacturing scale partnerships.

Funding Activity The company secured a 150 million debt refinancing in May 2026, indicating access to capital for expansion, clinical development, or capacity enhancements that could benefit suppliers offering scalable manufacturing, supply chain optimization, or financing-linked collaboration programs.

Litigation Landscape Multiple securities-related lawsuits in early 2026 suggest heightened risk awareness and potential diligence needs; selling opportunities exist for risk management, regulatory compliance services, and quality assurance or remediation support in manufacturing and investor communications.

Tech Stack Adoption of diverse enterprise tools (Salesforce Marketing Cloud, iCIMS, DocuSign, SAS, SharePoint, WordPress) indicates a tech-forward organization receptive to integrated digital solutions, marketing automation, CRM enhancements, and secure e-signature workflows that could streamline partnerships and supplier onboarding.

Market Position As a mid-sized pharmaceutical manufacturer with growth ambition and proximity to peers in the 50–100M revenue band, there is opportunity to offer contract development and manufacturing, formulation optimization, and scale-up services to support their next phase of commercial production.